Cartalax Dosage, half-life & reference guide
Also known as AED peptide · Ala-Glu-Asp · Kartalax
A short peptide from the Russian bioregulator program behind Epitalon and Pinealon, which its developers describe as a bioregulator for cartilage and joints. In cell studies it raised the genes cartilage is built from in aging stem cells and damped the aging signals of cartilage cells, and in rats it slowed bone loss. No human study has been published, and nearly all the research is by its developers.
- How often
- Daily
- Half-life
- Unknown
- Evidence
- ●
●●Emerging - Routes
- SubQ, Oral capsules
No human study has tested a dose of Cartalax: the amounts people run are their own protocol, not a reference.
How it works.
A tripeptide, Ala-Glu-Asp (AED), from the Russian bioregulator program of Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, the group behind Epitalon and Pinealon. Its developers found it in their peptide extract of animal cartilage and describe it as the bioregulator of cartilage and the musculoskeletal system: in their scheme each short peptide regulates one tissue, by binding DNA and changing which genes are read. In aging human stem cells grown in the lab it raised the genes and proteins cartilage is built from (SOX9, aggrecan, type II collagen) and in chondrocyte cultures it damped the signals of cell aging; in rats with induced bone loss it kept bone density from falling. No human study of Cartalax has been published, and almost all of its research comes from its developers.
Commonly reported: Easier, less stiff joints over a few weeks for some, quick relief for a few and nothing at all for others; it is often added to BPC-157 and TB-500 or the KLOW blend.
Week by week.
What to expect in the first 8 weeks
- Onset
- Days to weeks (commonly reported)
- Peak effect
- Weeks (commonly reported)
- Duration
- Courses of 10–30 days (community practice)
Day 1–7Community
Most feel little in week one
Commonly reported: little to feel in the first days, with a few describing quick relief in a sore joint. A line each morning on how your joints feel gives you an honest read to compare against later.
Updated Oct 2026
Day 7–21Community
Joints start to feel easier
Commonly reported: a gradual easing of stiffness and better day-to-day comfort over the second and third weeks, for some. Others notice nothing at all, the most common letdown in user reports.
The science
No study has measured how fast anything changes in people. In aging human stem cells grown in the lab, AED raised the genes and proteins cartilage is built from: SOX9, aggrecan, type II collagen and COMP (Myakisheva 2023).
Sources- Myakisheva et al. (2023)
Updated Oct 2026
Day 21–60Community
Time for an honest look
A typical course ends around here: its developers' capsules are labelled for a month, and injected courses commonly run 10–20 days. Compare against how your joints felt on day one; the next course usually waits months.
The science
No study has tested a course length or what lasts after one. In chondrocyte cultures, AED brought the aging signals that build up in osteoarthritis (p16, p21, p53, TNF-α and IL-1α) back toward normal and restored SIRT1 (Myakisheva 2023).
Sources- Myakisheva et al. (2023)
Updated Oct 2026
Any dayAnimal
What Cartalax is built on
A tripeptide from the same Russian bioregulator program as Epitalon and Pinealon, which its developers describe as cartilage's own regulator. Its evidence is cell studies and one rat study, almost all by its developers and much of it in Russian journals; no human study has been published.
The science
AED is one of the short peptides its developers identified in their cartilage extract (Linkova 2023). In aging human stem cells it raised SOX9, aggrecan, type II collagen and COMP (Myakisheva 2023); in rat skin cells aging in culture it lowered MMP-9, an enzyme that breaks down tissue, and cut programmed cell death (Lin'kova 2016). In rats after ovary removal it kept bone density from falling, less well than the cartilage extract (Povorozniuk 2007). The developers' claims of use in people with osteoarthritis rest on their 2008 patent and their own reviews; no such study is indexed in PubMed, and no trial is registered on ClinicalTrials.gov.
Sources- Linkova et al. (2023)
- Myakisheva et al. (2023)
- Lin'kova et al. (2016)
- Povorozniuk et al. (2007)
Updated Oct 2026
With BPC-157 and TB-500Community
The cartilage piece of a healing stack
Commonly reported: Cartalax is added to BPC-157 and TB-500, or the KLOW blend, when a joint or an old injury is the target, as the piece aimed at cartilage. No study has tested it with either.
The science
BPC-157's and TB-500's cases are animal work on blood supply and repair cells (see their entries); the one controlled test of the two together, in rats with repaired Achilles tendons, found the pair added nothing over either alone (Biçer 2026). Cartalax's case is cell work on cartilage-building genes (Myakisheva 2023). Nothing has combined Cartalax with either.
Sources- Biçer et al. (2026)
- Myakisheva et al. (2023)
Updated Oct 2026
Day 1 is the day you start it.
No human study of Cartalax has been published. Timelines are what users commonly report; the mechanism comes from cell studies and one rat study, almost all by its developers.
Preliminary research
A typical run.
Run notes
- Cycle
- Run in courses rather than continuously, like the other bioregulators. Its developers' capsules are labelled for a one-month course, repeated after 3–6 months; injected courses commonly run 10–20 days, a few times a year, and some run for weeks longer. No study has tested a course length.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- No timing has been studied. Its developers' capsules are taken with meals.
- Routes
- SubQ injection, Oral capsules
- Stacks
- BPC-157, TB-500
Safety.
Common side effects
- Injection-site redness or itch
- Stinging on injection
- Mild fatigue early in a course
- Light headache
Interactions
No interaction studies exist, including with BPC-157 and TB-500, the peptides it is most often stacked with.
Safety notes
No safety study exists: no human trial of Cartalax has been published, so its side effects are known only from user reports, and nothing is known about long-term use. Discuss with your clinician before use, particularly during pregnancy or breastfeeding.
Questions people ask.
What is Cartalax?
A short peptide from the Russian bioregulator program behind Epitalon and Pinealon, which its developers describe as a bioregulator for cartilage and joints. In cell studies it raised the genes cartilage is built from in aging stem cells and damped the aging signals of cartilage cells, and in rats it slowed bone loss. No human study has been published, and nearly all the research is by its developers.
How is Cartalax dosed in research?
The library carries no reference dose for Cartalax. No human study has tested a dose of Cartalax: the amounts people run are their own protocol, not a reference.
How long does Cartalax last?
The half-life of Cartalax is unknown (never measured).
What do people report on Cartalax?
Commonly reported on Cartalax: easier, less stiff joints over a few weeks for some, quick relief for a few and nothing at all for others; it is often added to BPC-157 and TB-500 or the KLOW blend.
Is Cartalax safe?
The research basis for Cartalax is emerging: primarily preclinical / limited human data. Common side effects in the library: injection-site redness or itch, stinging on injection, mild fatigue early in a course and light headache.
What does Cartalax stack with?
Common stacks for Cartalax: BPC-157 and TB-500.
Research.
Reference.
- Cadence
Daily
- Half-life
Unknown
Unknown (never measured)
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
PepVault for iPhone
Track Cartalax in PepVault
Log every dose, with reminders on your schedule. 7 days free on the yearly plan for new subscribers.
Reviewed How we check the library